Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study.

J Clin Med · 2023 · PMC10179221 · PMID 37176672

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Among these, risankizumab, an innovative biologic drug selectively targeting IL23, showed highly significant results in terms of efficacy and safety in clinical trials [ 13 , 14 , 15 , 16 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.